Stocks
Ophthotech CorpOPHT
HealthcareBiotechnology
A clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, including age-related macular degeneration. Its lead candidate, Zimura, targets complement factor C5 and has been evaluated in clinical trials for various ocular conditions. Investors track the company for its potential in the ophthalmic drug market and its pipeline developments.
Congressional Interest in Ophthotech Corp (OPHT)
1 member of Congress has disclosed 1 trade in Ophthotech Corp (OPHT), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading OPHT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-08-07 | MICHAEL T. MCCAUL | sell | $1K-$15K |